Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol®)

European Journal of Cancer

Volumn 32, Issue SUPPL. 4, 1996, Pages

  Schuchter, L M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

amifositine; therapeutic index; toxicity; WR 1065; WR 2721

Indexed keywords

AMIFOSTINE; CISPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CELL PROTECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL;

AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASMS;

EID: 0029990864     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00316-4     Document Type: Article

References (19)

1. Cysteine protection x-irradiation
2. The current status of toxicity protectants in cancer therapy
3. The current status of WR-2721 (amifostine): a chemotherapy and radiation therapy protector
4. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumour properties
5. Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide
6. Biochemical modification of the toxicity and anti-tumor effect of 5-fluorouracil and cisplatinum by WR-2721 in mice
7. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse
8. Protection against cisplatin neurotoxicity in cultured dorsal root ganglion cells by WR-2721
9. WR-2721 protects neurons of the snail Lymnaea stanalis from cisplatin-induced toxicity
10. Effects of modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin/DNA adducts in vitro
11. Effect of chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma
12. Amifostine (WR-2721) enhances cisplatin/vinblastine effect on nonsmall cell lung carcinoma cells in vivo but not in vitro
13. Phase I trials of WR-2721 and cisplatinum
14. Cisplatin neuropathy: risk factors, prognosis, and protection by WR-2721
15. WR-2721 and high dose cisplatin: an active combination in the treatment of metastatic melanoma
16. High dose cisplatin and WR2721 in metastatic melanoma
17. High dose cisplatin plus WR-2721 in a split course in metastatic melanoma
18. Phase II study of WR-2721/cisplatin/vinblastine, followed by thoracic radiation (RT) and WR-2721, in stage III non-small cell lung cancer (NSCLC)
19. Phase II trial of amifostine, cisplatin and vinblastine for metastatic nonsmall cell lung cancer